URINARY VEGF Levels in GBM Patients on Radiation Treatment Protocol

This study is not yet open for participant recruitment.

Verified by Tel-Aviv Sourasky Medical Center, September 2006

Sponsors and Collaborators:	Tel-Aviv Sourasky Medical Center RTOG
Information provided by:	Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:	NCT00392548

Purpose

Study of the urinary vascular endothelial growth factor (VEGF) levels in patients with glioblastoma, receiving standard therapy.

Hypothesis: that urinary VEGF levels can serve as a predictor of treatment response and survival.

Condition
Glioblastoma

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Urinary VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

Further study details as provided by Tel-Aviv Sourasky Medical Center:

Estimated Enrollment:	130
Study Start Date:	October 2006
Estimated Study Completion Date:	October 2006

Detailed Description:

Measurement of urinary VEGF levels pre treatment,immediately after treatment, and 1 month after treatment

Eligibility

Criteria

Inclusion Criteria:

Patient must be enrolled on an RTOG GBM study that prescribes 6000 cGy of radiation therapy.
Patient must meet the eligibility requirements for the RTOG treatment study. (If the patient is deemed retrospectively ineligible for the RTOG treatment study, the patient will likewise be ineligible for this study.)
Patient must sign a study-specific informed consent for RTOG 0611 prior to study entry.

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00392548

Contacts

Contact: Deborah T Blumenthal, MD	011972524266304	deborahblumenthal@gmail.com
Contact: Lina Vizelman, BS	01197236977532	linav@tasmc.health.gov.il

Locations

Israel
tel Aviv Sourasky Medical Center
Tel Aviv, Israel, 64239

Sponsors and Collaborators

Tel-Aviv Sourasky Medical Center

RTOG

Investigators

Principal Investigator:

Deborah T Blumenthal, MD

Tel-Aviv Sourasky Medical Center

More Information

Study ID Numbers:	RTOG0611
Study First Received:	October 25, 2006
Last Updated:	October 25, 2006
ClinicalTrials.gov Identifier:	NCT00392548
Health Authority:	Israel: Ministry of Health

Keywords provided by Tel-Aviv Sourasky Medical Center:

GBM
glioblastoma
urine

VEGF
radiation
Patients must be enrolled to an RTOG GBM study that prescribes 6000 cGy of radiation therapy.

Study placed in the following topic categories:

Neuroectodermal Tumors
Glioblastoma
Glioblastoma multiforme
Astrocytoma
Neoplasms, Germ Cell and Embryonal

Neuroepithelioma
Glioma
Recurrence
Neoplasms, Glandular and Epithelial

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial

ClinicalTrials.gov processed this record on January 14, 2009